Borderline Resectable Pancreatic Adenocarcinoma Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Borderline Resectable Pancreatic Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma+1 more
PanTher Therapeutics26 enrolled6 locationsNCT06673017
Recruiting
Phase 2

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang University40 enrolled2 locationsNCT07240766
Recruiting
Phase 1Phase 2

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic AdenocarcinomaLocalized Pancreatic Adenocarcinoma
Amsterdam UMC, location VUmc66 enrolled4 locationsNCT06384560
Recruiting
Phase 1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04484909
Recruiting

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic Adenocarcinoma
Ruijin Hospital119 enrolled2 locationsNCT07080021
Recruiting
Phase 2

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Pancreatic AdenocarcinomaPancreatic NeoplasmBorderline Resectable Pancreatic Adenocarcinoma
Erasme University Hospital256 enrolled10 locationsNCT05083247
Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

SurgeryQuality of LifePancreas Cancer+6 more
Umeå University300 enrolled1 locationNCT05356039